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Abstract
Cardiomyopathies might lead to end-stage heart disease with the requirement of drastic
treatments like bridging up to transplant or heart transplantation. A not precisely known pro-
portion of these diseases are genetically determined. We genotyped 43 index-patients (30
DCM, 10 ARVC, 3 RCM) with advanced or end stage cardiomyopathy using a gene panel
which covered 46 known cardiomyopathy disease genes. Fifty-three variants with possible
impact on disease in 33 patients were identified. Of these 27 (51%) were classified as likely
pathogenic or pathogenic in the MYH7, MYL2, MYL3, NEXN, TNNC1, TNNI3, DES, LMNA,
PKP2, PLN, RBM20, TTN, and CRYAB genes. Fifty-six percent (n = 24) of index-patients
carried a likely pathogenic or pathogenic mutation. Of these 75% (n = 18) were familial and
25% (n = 6) sporadic cases. However, severe cardiomyopathy seemed to be not character-
ized by a specific mutation profile. Remarkably, we identified a novel homozygous PKP2-
missense variant in a large consanguineous family with sudden death in early childhood and
several members with heart transplantation in adolescent age.
Introduction
Although multiple studies on genetics of cardiomyopathies [1–7] indicated a notable propor-
tion of genetic cases, the genotyping of end-stage heart failure patients is not well established
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in clinical practice. The Human Gene Mutation Database (HGMD, [8]) lists 156 genes related
to cardiomyopathies that can all necessitate heart transplantation (HTx) in the end-stage of the
disease. The genes that are most commonly affected are desmosomal genes in case of arrhyth-
mogenic right ventricular cardiomyopathy (ARVC) [9] and genes coding for components of
the sarcomere, Z-disk, intercalated disk, cell membrane, ion channel, and nucleus in case of
dilated cardiomyopathy (DCM), respectively [2, 4, 5, 7, 10]. Genotyping of patients evaluated
for HTx, bridged to transplantation by ventricular assist device implantation (VAD) or already
transplanted is still not routinely performed although this contributes to early family manage-
ment [11]. Both HTx and VAD implantation may cause a considerable psychological burden
for the patients and their relatives. Therefore, especially in these families a possible genetic
cause of the disease is a pressing question. The knowledge of the disease-causing mutation sup-
ports the early identification of family members with asymptomatic disease or at risk for devel-
oping disease. An early patient management might prevent sudden cardiac death and might
prevent or at least delay HTx or VAD implantation [11]. However, at present there are no spe-
cific guidelines available on how to treat genotype positive yet phenotype negative individuals.
The goal of this study was to evaluate whether genotyping of patients with end-stage cardio-
myopathy might provide the chance to identify characteristic genes or mutations that are asso-
ciated with the most severe course of this disease. Furthermore, we speculate that a notable
proportion of sporadic cases are genetically determined. Therefore, we analysed 46 disease
genes in 43 index-patients with end-stage cardiomyopathy by next generation sequencing
(NGS). We found that the majority of DCM-cases (60%) and 40% of ARVC-cases were carriers
of an at least likely pathogenic (class 4 or 5) mutation following the American College of Medi-
cal Genetics and Genomics (ACMG) guidelines for variant classification [12]. Of note, we
identified a novel homozygous PKP2-gene mutation, which is associated with dilated
cardiomyopathy.
Material and methods
Study population
We included patients with no-ischemic severe heart failure with need of HTx or mechanical
circulatory support. We also included patients transferred to our center for the evaluation to
list for HTx. A positive family history for cardiomyopathy or in case of presumed sporadic
cases age at diagnosis 40 years were defined as additional study criteria. This led to the inclu-
sion of 30 DCM (21 familial, 9 sporadic) and 3 RCM index-patients (1 familial, 2 sporadic).
Additionally, for ARVC-cases an at least possible diagnosis of ARVC according the revised
Task Force Criteria [13] and the modified criteria [14] in case of pediatric patients (ARVC-01
and ARVC-08) was a prerequisite. Ten ARVC index-patients (6 familial, 4 sporadic cases) met
the criteria and were included in the study. Of these 4 patients had ARVC with left ventricular
dilation and had been treated by HTx, and total artificial heart implantation, respectively. The
remaining 6 cases were diagnosed with arrhythmias and right ventricle enlargement/failure.
Four of them underwent HTx, two cases were evaluated for HTx and treated with an ICD. All
patients (n = 43) were genotyped in 46 cardiomyopathy-associated genes (see below).
DCM and RCM were diagnosed according to established criteria [15, 16]. Clinical charac-
teristics of the index-patients are summarised in Table 1, S1 and S2 Tables. All patients were
of European/Caucasian origin. The written informed consent of all patients was obtained. In
case of minors patient written informed consent of the parents were obtained. The study was
approved by the local ethics committee (Ruhr University Bochum, Bad Oeynhausen, Ger-
many, Reg.-No.27.1/2011). This study was complied with the Declaration of Helsinki.
Genetic cases in advanced cardiomyopathy
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Table 1. Clinical, familial and genetic data of 50 patients with advanced or end stage cardiomyopathy.
Patient
ID
Gender Age at
diagnosis
(Years)
Treatment NYHA*/Task Force
classification†
Age at
HTxa/
VADb
Family history‡ Affected Genes
(ACMG class)
DCM-01 m 1 VAD, HTx IV 13a Sporadic§ MYH7 (4), MYL2
(4)
DCM-02 m 31 pre HTxII III - Sporadic TTN (3)
DCM-03 m 68 ICD, VAD III 69b Son with DCM TTN (4), DSC2 (2),
TTN (3)
DCM-04 m 30 HTx IV 62a Mother (61y) died from DCM TTN (4), DSP (3)
DCM-05 m 11 HTx IV 14 Older brother with DCM and HTx TNNC1 (4),
TNNC1 (3)
DCM-06 m < 1 VAD, HTx IV <1a Sporadic TTN (3)
DCM-07 m 35 ICD, VAD,
HTx
IV 47a Cousin with HTx, sister with suspicion of DCM,
father and brother died from heart disease,
sister with heart disease
LMNA (5)
DCM-08 m 23 VAD, HTx IV 23a Father with DCM TTN (3)
DCM-09 f 41 ICD, AMB II#,** - SCD of father (40y), brother died from heart
disease (23y)
DES (5), TTN (3)
DCM-10 m 33 ICD, HTX IV 37 Mother and aunt with HTx, brother and niece
with DCM
DSP (2)
DCM-11 m 36 ICD, HTx III-IV 48a Two cousins died from SCD DES (4)
DCM-12 m 18 ICD, VAD III-IV 29b Sporadic TTN (4), TNNT2
(3)
DCM-13 m 39 pre HTxII I#,** - Father with DCM and HTx LMNA (4), TTN (4)
DCM-14 m 60 ICD, HTx III 63a Mother and two brothers died from heart
disease, sister with DCM and HTx
RBM20 (4), DSP
(3)
DCM-15 m 32 HTx III 40a Son with DCM and HTx, sister with DCM RBM20 (5), TTN
(3)
DCM-16 f 20 ICD, VAD III-IV 32b Sporadic TTN (4), TTN (3)
DCM-17 m 14 ICD,HTx III 59 Father and paternal uncle with SCD DES (5)
DCM-18 f n.a ICD, HTx IV 52a Monozygotic twin sister (45y) died from heart
disease
LMNA (5)
DCM-19 m 5 ICD, VAD IV 22b Sporadic NEXN (4), MYH7
(4)
DCM-20 m 35 ICD, pre
HTx
II-III - Father with DCM TTN (4), DSP (3)
DCM-21 f n.a ICD, pre
HTx
II#,** - Father died from DCM, deceased brother with
VAD, son and daughter with heart disease
TTN (3)
DCM-22 f 59 pre HTxII II#,** - Brother with HTx, another brother with VAD TTN (4)
DCM-23 f n.a. HTx IV 14a SCD of 2 brothers in childhood, 2 siblings with
DCM and HTx in adolescent age
PKP2 (4), LAMA4
(2)
DCM-24 f 30 VAD IV 31b Sporadic TTN (3)
DCM-25 m 40 ICD, pre
HTx
II-III - SCD of 3 maternal uncles, son with DCM Unknown
DCM-26 f n.a HTx IV 16a Sporadic Unknown
DCM-27 m 38 VAD, HTx IV 53a Father died from DCM (43y), brother and
sister with heart disease
Unknown
DCM-28 m 37 ICD, VAD,
HTx
IV 52a SCD of maternal grandmother (60y) Unknown
DCM-29 m 31 HTx IV 42a Paternal grandfather (51y) and father (46y)
deceased from heart disease
Unknown
DCM-30 m 36 ICD, pre
HTx
II** - Sporadic Unknown
(Continued )
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DNA analysis
DNA was isolated from white blood cells using standard techniques (High Pure PCR Template
Preparation Kit1, Roche Diagnostics GmbH, Mannheim, Germany) and prepared for cardiac
gene enrichment re-sequencing on a MiSeq1 next generation sequencing system according to
manufactures instructions (TruSight™ Rapid Capture Sample Preparation Kit). All patients
were screened for variants in 46 cardiomyopathy genes using the TruSight™ Cardiomyopathy
gene panel. The evidence linking these genes to cardiomyopathy has been published previously
[17] (for gene list see S3 Table). Enrichment, sequencing kits and sequencing system were
Table 1. (Continued)
Patient
ID
Gender Age at
diagnosis
(Years)
Treatment NYHA*/Task Force
classification†
Age at
HTxa/
VADb
Family history‡ Affected Genes
(ACMG class)
RCM-01 f 12 VAD, HTx IV 13a Sporadic MYL3 (3)
RCM-02 m < 1 VAD IV <1b Sporadic TNNI3 (4)
RCM-03 m 19 HTx IV 12a Mother (42y) with muscular dystrophy died
from heart disease
CRYAB (5)
ARVC-
01
m 14 ICD DD††** Sporadic PKP2 (5)
ARVC-
02
m 35 ICD, HTx DD 36a SCD of father, brother with heart disease MYH7 (3)
ARVC-
03
m 67 ICD PD Sporadic PRKAG2 (3)
ARVC-
04
f 35 ICD, TAH DD 55b SCD of maternal grandmother and uncle,
sister with DCM
PLN (5), MYH6 (3),
TTN (2)
ARVC-
05
f 45 ICD, HTx DD 47a Maternal grandfather with SCD LMNA (4), PKP2
(3)
ARVC-
06
f 21 ICD, HTx DD 32a ARVC with SCD of father and brother PKP2 (5), PKP2
(3), RYR2 (3), TTN
(3)
ARVC-
07
m 40 ICD, HTx BL 62a Paternal great-grandfather and father with
heart disease and premature death
DES (3)
ARVC-
08
m 16 ICD, HTx BL†† 21a Sporadic Unknown
ARVC-
09
f 42 VAD PD 45b Sporadic Unknown
ARVC-
10
f n.a ICD, HTx DD 46a Two maternal great-uncles with SCD Unknown
Abbreviations
a = age at HTx, ACMG class 2 = likely benign, ACMG class 3 = variant of uncertain significance, ACMG class 4 = likely pathogenic, ACMG class 5 =
pathogenic, AMB = ambulatory, ARVC = arrhythmogenic right ventricular cardiomyopathy
b = age at VAD, DCM = dilated cardiomyopathy; f = female, FS = fractional shortening, HTx = heart transplantation, ICD = implantable cardioverter
defibrillator, ID = identification, m = male, n.a. = not available, RCM = restrictive cardiomyopathy, SCD = sudden cardiac death, TAH = total artificial heart,
VAD = ventricular assist device; y = year(s).
*New York Heart Association functional classification of heart failure before VAD or HTx, respectively.
†Classification according Task Force Criteria [13].
‡Familial disposition for cardiomyopathy due to pedigree analysis and anecdotal evidence.
§Sporadic = isolated cases without family history.
IITreated medically.
#Progressive cardiomyopathy with familial disposition due to pedigree analysis or anecdotal evidence, respectively.
**Not yet listed for HTx but in the long term surveillance program.
†† Classification according to Task Force Criteria [13] and consideration of the modified pediatric criteria [14]. For pedigrees see S2 Fig.
https://doi.org/10.1371/journal.pone.0189489.t001
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supplied by Illumina Inc, San Diego, CA, USA. For reads alignment and base calling Illumina´s
automated work flow was used (BWA [18], GATK [19], and SAMtools [20]).
A minimum read depth of 20 reads was set as quality cut-off (quality data see S4 Table). For
variant annotation the VariantStudio™ v2.1 software provided by Illumina Inc with the UCSC
Genome Build hg19 as reference was used. We filtered variants located in exon- and consensus
splice-sequences (± 1 and 2 position) with a global minor allele frequency (MAF)0.0005
according to the data provided by the Exome Aggregation Consortium (Version 0.3, ExAC data
and browser (beta) Version) [21]. Synonymous variants were not taken into account. Variants of
interest were verified by Sanger sequencing (BigDye1 Terminator v1.1 Cycle Sequencing Kit,
ABI PRISM1 3100 genetic analyzer, Applied Biosystems, Foster City, CA, USA).
Variant classification
This study was primarily designed to identify dominant single gene mutations with clear clinical
impact on ARVC or other cardiomyopathy subtypes. Therefore the guidelines [12] of the Amer-
ican College of Medical Genetics and Genomics (ACMG) were considered for variant classifica-
tion. The ACMG defined five variant classes: class 5, pathogenic; class 4, likely pathogenic; class
3, variant of uncertain significance (VUS); class 2, likely benign; class 1, benign. For use on
mainly private variants the criteria and rules for classification have been adjusted (for details see
S1 Methods). The cut-off for the minor allele frequency (MAF) of variants of interest was set to
a value0.0005 and thus within the range of the respective disease prevalence (http://www.
orpha.net) [22]. The ExAC browser [21] was used as reference for allele frequencies. Only fre-
quencies of the non-Finnish European population were taken into account. Original reports
listed in the Human Mutation Database Professional 2015.1 (HGMD1) [8] and the ARVC
Genetic Variants Database [23, 24] were reviewed concerning variant classification. Deleterious
effect of a variant was considered when3 prediction tools forecasted the variant to be deleteri-
ous (MutPred [25], SNP&GO [26, 27], Fathmm [28], and PolyPhen-2 (Polymorphism Pheno-
typing v2, humVar) [29]). In case of the TTN-gene only variants affecting the cardiac titin
isoforms N2B and/or N2BA were further investigated. In this manuscript only (likely) patho-
genic gene variations are referred to as ‘mutation’ while (likely) benign variants, variants of
uncertain significance and gene variations in a general context are called ‘variant’.
Gene and variant nomenclature
The nomenclature of sequence variants based on the rules of the Human Genome Variation
Society (HGVS, www.hgvs.org). Nucleotide and amino acid numbering refers to the reference
sequences given by the National Center of Biotechnology Information (NCBI, http://www.
ncbi.nlm.nih.gov) (S3 Table). In case of TTN the nomenclature refers to the longest predicted
isoform (NM_001267550.1, NP_001254479.1). All variations listed in this manuscript were
submitted to ClinVar (http://www.ncbi.nlm.nih.gov/clinvar) using the submission name
HDZNRW. An already existing listing of the study variants in the ClinVar database was
checked. Some of them have been reported by others, a few with conflicting interpretation of
pathogenicity. The listing of TTN variants was only partially verified because of inconsistent
nomenclature based on different isoforms.
Results
Patient cohort
The study cohort comprised 43 unrelated index-patients (29 male, 14 female) with cardiomy-
opathy of different types (Fig 1). Of these, 33 patients presented with end-stage disease and
Genetic cases in advanced cardiomyopathy
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already underwent implantation of VAD and/or HTx. Ten patients were evaluated for HTx
due to clinical signs of advanced cardiomyopathy. Seventy-nine percent of DCM- and RCM-
patients were in New York Heart Association (NYHA) classification III or IV (Table 1). Six
ARVC-patients were classified with definite diagnosis (DD), 2 patients with possible (PD), and
2 patients with borderline diagnosis (BL) (Table 1). The mean age at diagnosis was not signifi-
cantly different in DCM- (0031±17 years) and ARVC-cases (35±17 years) (S1 Fig). Due to the
small number statistical evaluations for RCM-cases were not possible in this study (Table 1).
Familial disposition for the cardiomyopathy due to pedigree analysis and anecdotal evidence
Fig 1. Variant carrying genes. In DCM-cases TTN carried the most variants. Of 19 TTN-variants in DCM-cases, 6 were
truncating variants. The other affected genes were TNNT2, TNNC1, RBM20, PKP2, NEXN, MYL2, MYH7, LMNA, DSP, and
DES. In ARVC-cases predominantly PKP2- and TTN-variants were identified. Further variants were found in the genes
PRKAG2, PLN, MYH7, MYH6, LMNA, and DES. In the cohort of the RCM-cases variants in 3 different genes were identified:
TNNI3, MYL3, and CRYAB. ACMG class 3–5 = variant of uncertain significance, likely pathogenic, pathogenic, respectively.
https://doi.org/10.1371/journal.pone.0189489.g001
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was suspected in 21of 30 DCM, 6 of 10 ARVC and once in RCM (n = 3) cases (Table 1). Spo-
radic cardiomyopathy was suspected in 15 patients. Where available the pedigrees illustrating
heart disease within the families and variant co-segregation/penetrance are shown in S2 Fig.
Genotyping results
In the entire study population we identified (likely) pathogenic mutations in 56% of index-
patients (18 familial, 6 sporadic cases). Nine patients were carriers of a pathogenic and 15 car-
ried a likely pathogenic mutation. VUS were found in 21% of cases (4 familial, 5 sporadic
cases). An only likely benign variant was identified in one patient and variants with an allele
frequency exceeding the disease prevalence and therefore not further investigated were identi-
fied in 9 patients. This means that in total in 23% (n = 10, 6 familial, 4 sporadic cases) of
patients no disease associated variants were identified (Fig 2).
Of the DCM-patients, 60% (n = 18) had pathogenic or likely pathogenic mutations, respec-
tively, while 17% (n = 5) were at least carriers of VUS. One DCM-case (DCM-10) had only a
likely benign variant. In DCM-patients 25–30 only polymorphisms were identified (Fig 3).
The proportion of pathogenic or likely pathogenic mutations was 66% in familial DCM and
44% in sporadic DCM-cases. In 40% (n = 4; 3 familial, 1 sporadic case) of ARVC-cases patho-
genic or likely pathogenic mutations were found (Fig 3). In the entire ARVC-cohort (likely)
pathogenic mutations were identified in 50% of familial cases (n = 6). In sporadic cases (n = 4)
one pathogenic mutation was identified. Three ARVC-patients each were carriers of VUS or
polymorphisms, respectively (Fig 3). In the RCM-cases (n = 3) two patients with pathogenic or
likely pathogenic mutations (1 familial, 1 sporadic case), respectively, were identified (Fig 3).
Variant classification
In 19 of 46 genes, a total of 57 variants were found (Fig 1). We identified 41 missense variants
in addition to 3 nonsense, 7 frameshift, 3 in frame insertion/deletion, and 3 canonical splice-
site variants. Out of these, 15 had entries in the mutation-databases [8, 24], whereas 42 variants
were previously not described in context with a disease. We evaluated the pathogenic evidence
Fig 2. Distribution of variant classes. We genotyped 43 index-patients. Of these 18 familial and 6 sporadic
cases carried (likely) pathogenic mutations. At least variants of uncertain significance were found in 4 familial
and 5 sporadic cases. Only likely benign variants or variants with an allele frequency exceeding the disease
prevalence were identified in 10 patients (6 familial, 4 sporadic cases). Familial disposition for the
cardiomyopathy is based on pedigree analysis and family reports. Abbreviations: F = familial cases, no
label = sporadic cases.
https://doi.org/10.1371/journal.pone.0189489.g002
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of all variants (S5 and S6 Tables) and classified four variants likely benign, whereas fifty-three
variants were classified (likely) pathogenic or VUS, respectively. The potentially disease related
variants affected 18 genes. In total, we identified 9 pathogenic mutations in 9 index-patients (8
familial cases, 1 sporadic case) in 6 different genes (LMNA, DES, RBM20,CRYAB, PKP2, PLN).
We identified two or more variants in 14 DCM- and 3 ARVC-cases.
In DCM-patients TTNwas the most frequently affected gene (51% of variants; Fig 1). In
the DCM-cohort, pathogenic mutations were identified in DES, LMNA, and RBM20 (Table 1,
S5 Table), whereas likely pathogenic mutations were found in MYL2, MYH7, TTN,TNNC1,
DES, LMNA, RBM20,NEXN, and PKP2. Remarkably, a homozygous PKP2-gene mutation
(c.2035C>T, p.His679Tyr) was identified in a large Turkish family (DCM-23). As expected,
Fig 3. Classification of the variants. In 60% of DCM- and 40% of ARVC-cases pathogenic and/or likely
pathogenic mutations were identified. At least variants with uncertain significance were found in 17% DCM-
and 30% ARVC-cases. No relevant variants (MAF >0.0005 in etiological matching controls) were found in
22% and 30% of DCM-, and ARVC-cases, respectively. In RCM-cases, 2 pathogenic and/or likely pathogenic
mutations and 1 variant with uncertain significance were identified. Abbreviations: class 2 = likely benign,
class 3 = variant of uncertain significance, class 4 = likely pathogenic, class 5 = pathogenic.
https://doi.org/10.1371/journal.pone.0189489.g003
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PKP2 was the most frequently affected gene in ARVC-patients. Pathogenic mutations in the
ARVC-cohort were found in PKP2 and PLN, a likely pathogenic mutation was found in
LMNA (Table 1, S5 Table). Surprisingly, no further desmosomal genes were affected in
ARVC-cases. In the RCM-cases two patients with pathogenic or likely pathogenic mutations
in TNNI3 and CRYAB, respectively, were identified (Table 1, S5 Table). The median age at
diagnosis in DCM- and ARVC-cases (33 and 36 years, respectively) was not significantly dif-
ferent in dependence of variant classification (S3 Fig).
Twenty-one TTN variants (7 TTN-tv (premature stop codon with/without preceded frame-
shift, and canonical ± 1 or 2 splice site variants), 13 missense, 1 in-frame insertion) were iden-
tified in 16 (37%) of 43 index-patients (Table 1, S5 Table). In DCM-patients TTN-variants
were more frequent (p<0.05; S4 Fig), whereas TTN-tv were increased by trend (p = 0.05, data
not shown) when compared to the other cardiomyopathies. Most of the TTN-variants (5 TTN-
tv, 7 missense) affected the titin domains spanning the A-band of the sarcomere. But also vari-
ants in the I-band (3x missense, 2x TTN-tv), M-line (2x missense, 1x in frame insertion), and
Z-band (1x missense) region of the protein were identified (S7 Table). All but one TTN-variant
were located within exons that are estimated to be incorporated in 100% of the cardiac TTN-
transcripts (PSI 100%, [6], http://cardiodb.org/titin) and might be expressed to a notable
amount. The TTN-variant found in patient DCM-2 is located within the I-band and is esti-
mated to be expressed only in 8% of the transcripts and is therefore believed to be of low dis-
ease relevance [6]. Seven (21%) of the 34 variant carriers of the present study had only TTN-
variant(s). Of these four patients had a single TTNmissense variant affecting the I-, A, and Z-
band of titin, respectively. One patient was carrier of a single TTN-tv in the A-band of the pro-
tein. DCM-16 had a splice and a missense TTN-variant in the A- and I-band, respectively.
DCM-24 is carrier of one in-frame duplication and two missense variants affecting the M-line
and the A-band, respectively (S5 and S7 Tables).
Family with a novel homozygous PKP2-gene mutation
We identified a novel homozygous PKP2-mutation c.2035C>T, p.His679Tyr in index-patient
DCM-23 (III/4, Fig 4A) who is a member of a large non-consanguineous Yezidi family. The
affected family members did not fulfill the ARVC Task Force criteria although PKP2 is gener-
ally associated with ARVC. Three genetically untested brothers died suddenly in childhood
(III/2, III/3, III/13; 11 years, 2 years, 7 days, respectively). She and two siblings (male (III/1),
female (III/10)) who are also homozygous for the PKP2-mutation underwent HTx in adoles-
cent age (14, 13 and 17 years, respectively) because of DCM (ECGs shown in S5 Fig.). The 57
years old mother (II/8), the 66 years old father (II/9) and two other siblings (III/8, III/12) who
are heterozygous mutation carriers have no signs of cardiac disease at all, suggesting a variant
co-segregation in an autosomal recessive mode. Surprisingly, the youngest sister (III/11, 18
years old) who is also a homozygous mutation carrier has currently no detectable signs of car-
diomyopathy as examined by ECG, TTE and MRI (data not shown). The suspected pathogenic
impact of PKP2 c.2035C>T was verified by analyzing whole exome data of the parents, an
unaffected sister (III/8), and the index-patient (III/4) (S1 Methods, S6 Fig). No other co-segre-
gating variant with an allele frequency0.0005 was found in cardiomyopathy genes listed in
HGMD (n = 156, S8 Table). A further indication of pathogenicity is the absence of PKP2
c.2035C>T in the ExAc browser with sufficient coverage of the gene region (read depth of 50
in 80% of the alleles). Analysis of the PKP2 locus (Fig 4B, S1 Methods) of the index-patient
(III/4) and her transplanted brother (III/1) revealed that they are homozygous for a haplotype
surrounding the PKP2-gene which largely overlaps between father (II/9) and mother (II/8),
suggesting that they are probably (distantly) related and the mutation might be inherited from
Genetic cases in advanced cardiomyopathy
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a common ancestor. In order to study the pathogenic mechanism of the mutation we investi-
gated plakophilin-2 mRNA and protein levels in explanted myocardium, but no differences
compared to controls were detected (S1 Methods, S7 and S8 Figs). Immunofluorescence stain-
ing of myocardial sections of the explanted heart of individual III/10 showed normal localiza-
tion of PKP2 at the intercalated disc (S1 Methods, S9 Fig). Thus, the mutation appears to have
no influence on the stability or subcellular localization of PKP2 within the myocardium. No
segregation with disease was observed for the nonsense variant in LAMA4 (S5 Table).
Discussion
This study focused on the genotyping of patients with advanced cardiomyopathy. Our inclu-
sion criteria lead to a study cohort mainly composed of patients who have been bridged for
heart transplantation and those already transplanted. The study design was set for the identifi-
cation of highly penetrant monogenic causes of cardiomyopathies.
Fig 4. Pedigree of DCM-23 family and PKP2 c.2035C>T co-segregation. A. Family members with HTx were homozygous carriers
of PKP2 c.2035C>T, p.His679Tyr whereas heterozygous carriers and the homozygous carrier III/11 had no signs of cardiomyopathy.
The LAMA4 variant did not co-segregate with disease (data not shown). Squares = males, circles = females. Deceased individuals are
indicated by slashes. Filled symbols indicate individuals with DCM. The index-patient is marked with an arrow. Genotypes are shown
by present (+) or by absent (-) of the gene variant. Abbreviations: SCD = sudden cardiac death, SID = sudden infant death, SUD =
unexplained sudden death. B. Haplotype analyses of PKP2 c.2035C>T mutation carriers from family DCM-23. Haplotypes associated
with the PKP2 mutation are shown in grey shaded areas. These haplotypes are identical in both parents (II/8, II/9) with the exception of
marker D12S61. Abbreviation: cM = centimorgan.
https://doi.org/10.1371/journal.pone.0189489.g004
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In total 57 variants were identified of which a high proportion were classified (likely) patho-
genic (51%). Surprisingly, (likely) pathogenic mutations were more frequently present in
DCM- than in ARVC-cases (60% versus 40%) although the majority of currently known
ARVC-genes with the exception of the minor disease genes TGFB3,CTNNA3 (see www.
arvcdatabase.info), [4], FLNC [30], and SCN5A [31] were analyzed. No variants were identified
even in one definite and one familial ARVC-case. This strongly suggests that other currently
unknown genes and/or genotypes are involved in the development of ARVC. Especially future
screening of the FLNC-gene could increase the variant detection because a prevalence of 1% of
truncating FLNC-mutations was reported in dilated and arrhythmic cardiomyopathies [30].
The mutation rate and profile in ARVC patients is in discrepancy to what have been
expected and published before by others. For example Groeneweg et al. [32] found a mutation
rate of 63% in a large ARVC-cohort, and in desmosomal genes a mutation rate of 40% was
reported [33]. The high mutation rate in our DCM-cohort is in the upper range of values
reported so far [2, 4, 5], in case of familial DCM it is in agreement with the findings of Cuenca
et al. [7]. Apparently, the mutation profiles differ notably between the different studies. As
expected, screening for gene variants is more successful in familial cases, but also in presum-
ably sporadic cases (likely) pathogenic mutations were identified in a noteworthy high number
(25%). In previous studies the prevalence of (potentially) pathogenic mutations in sporadic
DCM-cases was 8% and 68%, respectively [4, 5]. Our study cohort includes 12 patients with
disease onset at20 years of age assuming a genetic cause of disease although familial cardio-
myopathy was reported only for four cases. In eight patients an at least likely pathogenic gene
mutation was identified. These findings underscore the relevance to perform genetic testing
not only in suspected familial or sporadic cases with clinical clues suggestive of a particular/
rare genetic disease as recommended by the European Society of Cardiology [11] but in all
index-patients with an unknown etiology of the disease. Nevertheless, a characteristic muta-
tion profile for severe cardiomyopathy could not be defined.
Twenty five percent of our DCM cohort carried a TTN-tv mutation as reported for end-
stage DCM patients by Roberts et al. [6]. All TTN-tv mutations were classified as likely patho-
genic considering a high prevalence of TTN-tv in DCM-cohorts. TTN alternative splicing,
position-independent nonsense-mediated mRNA decay, an internal promoter, allele-specific
expression, structural and functional effects on sarcomere formation and force generation as
well as negative effects by incorporation of truncated titin into the sarcomere were discussed
as pathomechanisms for truncated titin [34–39]. Nevertheless, many additional data are
required for a better understanding of the mechanisms. Because of the background noise in
the general population TTNmissense variants were classified as VUS although recent large-
scale sequencing and functional analysis indicated strong impact on cardiomyopathies [40–
42]. Protein unfolding and domain destabilization was shown and/or predicted for TTNmis-
sense mutations located in the Z-disk [42], A/I junction region [43], and in the I-band [41] of
the protein, respectively. Decreased contractile force generation of a missense mutation
located in the Z/I-band junction was reported by Hinson et al. [35]. We identified 7 index-
patients with only TTN variants of different types affecting different protein regions. But
although functional data are available a final classification of TTN variants is not possible. Clas-
sification still based mostly on populations genetic data and one should keep in mind that new
functional data could lead to variant re-classification. Two patients carried multiple TTN vari-
ants. We did not investigate whether the gene was affected in a compound heterozygous or
homozygous way. Regardless, no data are available about patients with several TTN variants
and about a possibly increasing impact on disease. In agreement with recent data [6, 40] most
TTN-variants affected the inextensible A-band of titin and are incorporated in 100% of the car-
diac TTN-transcripts. [44, 45]. Patient DCM-16 is carrier of a TTN-tv and missense variant,
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had disease onset at the age of 20 years and VAD implantation when she was 32 years old.
Therefore, we suggest that TTN associated cardiomyopathy is present also in young adults
even though mostly it has its onset in the mid-late life period [40].
We identified a non-synonymous PKP2-mutation that in homozygous carriers led to mani-
festation of end-stage DCM at young age. This mutation might be characterized by a reduced
penetrance [46–48] since at present a homozygous 18 years old mutation carrier has no signs
of cardiac disease. We cannot rule out additional genetic factor(s) underlying the disease of the
family, although screening of all known cardiomyopathy associated genes gave no indication
for this. For PKP2 truncating mutations and interestingly, also for missense mutations hap-
loinsufficiency was indicated as a possible pathomechanism. Functional data to support this
assumption are limited. Kirchner et al. [49] reported decreased in vivo and in vitro protein
expression, impairment of protein structure and stability, and mislocation of plakophilin 2 in
the cytoplasm in case of PKP2 missense mutations. In addition for other PKP2 missense muta-
tions impairment of in vitro de novo desmosome assembly was described [50] and influence on
the expression of heat shock protein 90 was observed in case of two PKP2 truncating mutations
[51]. In our study the investigation of heart tissue of a homozygous mutation carrier revealed
no impact of PKP2 p.His679Tyr on plakophilin expression, stability and cell localization. This
might indicate a different pathomechanism as described above, although it must clearly be
pointed out, that in contrast to our in vivo data the characteristics of the mutations described
by Kirchner et al. based mainly on cell culture experiments. To our knowledge, this is the first
report of a PKP2-missense mutation causing recessively inherited DCM. No signs of hair or
skin abnormalities that were reported with other recessive desmosomal gene mutations [52,
53] were observed.
We detected a missense mutation in the Z-disk protein NEXN that was already described to
have a disruptive effect on the cardiac sarcomere in a DCM patient and a dominant negative
effect on Z-disk stability in zebrafish [54]. In accordance, we found this mutation in a male
DCM patient (DCM-19) who underwent VAD implantation at the age of 22 years. Based on
the functional studies described by Hassel et al. [54], an allele frequency clearly below the prev-
alence of DCM, and multiple computational evidence for a deleterious effect on the protein
this NEXNmutation must be classified as likely pathogenic according to ACMG guidelines.
Our study is the second report that links the NEXN gene to DCM and thereby strengthens the
importance of NEXN as a (minor) disease gene.
In our study, the usage of a sequencing panel with a comparatively small number of myopa-
thy associated genes for genotyping patients has historical reasons. But despite the limited
gene number it is important to point out that the majority of variants identified here were
novel variants in known major disease genes which are listed in the Mendelian Inheritance in
Man (MIM) compendium and which are covered by the 46-gene panel used here. As expected
besides these also variants in minor disease genes were identified.
Extensive variation screening in other (minor) disease genes in the whole exome and
genome, respectively, might provide further insights. However, variant classification with
respect to the impact on disease development and clinical course still remains the real chal-
lenge [12]. Due to limited availability of case reports, small families with limited co-segregation
data, and rarely available functional data, some ACMG [12] criteria were not applicable and
others had to be adjusted. But apart from this limitation, the ACMG guidelines were a suitable
tool for a uniform and differentiated variant classification. At present there are no guidelines
available how to treat non-symptomatic mutation carriers, due to the heterogeneous genetic
background of cardiomyopathies and the lack of pharmacological evidence for preventive
treatment. In order to overcome this limitation in the future more studies like the recent trials
that investigate the effect of drug treatment of pre-symptomatic PLN and LMNA mutation
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carriers are of impact (Clinical trials identifier: NCT01857856 and European Society of Cardi-
ology Congress 2016, Rome, Poster P4981, respectively).
Limitation
We excluded variants with an allele frequency above the disease prevalence. Therefore, this
study is not suited for the identification of a complex genotype or modifiers as well as variants
with reduced penetrance. Copy number variants and large DNA-rearrangements have not
been investigated. Only allele frequencies of the ethnically narrow non-Finnish European pop-
ulation provided by the Exome Aggregation Consortium were taken into account to define
variants of further interest. Variant screening was limited to 46 myopathy associated genes
covered by the TruSight™ Cardiomyopathy gene panel of Illumina. The recently described
ARVC and DCM disease gene FLNC and the ARVC disease gene SCN5Awere not screened
for variants.
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